NCM
ELTX icon

Northwest Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Northwest Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-350
Closed -$2.66K – 488
2024
Q1 		$2.66K Hold
350
– – ﹤0.01% 476
2023
Q4 		$2.92K Hold
350
– – ﹤0.01% 467
2023
Q3 		$2.96K Hold
350
– – ﹤0.01% 454
2023
Q2 		$3.33K Buy
+350
New +$3.21K ﹤0.01% 457

Other funds holding ELTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MHC
Meyer Handelman Company Rye Brook, New York $3.53B AUM 30.49% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Northwest Capital Management's ELTX Position: Q2 2024 in Review

Northwest Capital Management sold out of Elicio Therapeutics (ELTX) in Q2 2024, closing a stake of 350 shares — an estimated $2.66K sold.

Northwest Capital Management first reported a position in ELTX in Q2 2023 and held it in 4 quarters. The position peaked at $3.33K in Q2 2023. 20 funds tracked by Wall St. Rank hold ELTX as of Q2 2024.

  • Northwest Capital Management reported no remaining Elicio Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Northwest Capital Management sold 350 Elicio Therapeutics shares in Q2 2024, an estimated $2.66K.
  • Northwest Capital Management first reported a position in Elicio Therapeutics in Q2 2023 and held it in 4 quarters.
  • Northwest Capital Management's Elicio Therapeutics position peaked at $3.33K in Q2 2023.
  • 20 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2024.

Based on Northwest Capital Management's 13F filing for Q2 2024, filed 9 Jul 2024.